MediciNova, Inc., a biopharmaceutical firm, said that it has obtained a Notice of Allowance from the United States Patent and Trademark Office for a pending patent application for MN-166 (ibudilast) for the treatment of chlorine-induced acute...
Fortis Hospital Bannerghatta Road, recently achieved yet another significant clinical milestone with the successful completion of complex Robotic Kidney Transplant Surgeries for end-stage kidney disease
Hutchmed (China), a biopharmaceutical firm, declares that it has started a registrational stage III clinical preliminary of HMPL-306 in patients with changed isocitrate dehydrogenase (IDH) 1 or 2 backslid/refractory intense myeloid leukemia (AML)...
Instylla, Inc., a clinical-stage firm focused on creating fluid embolics for peripheral vascular embolotherapy, declared the completion of patient enlistment in the continuous Instylla HES Hypervascular Tumour Pivotal...
Moffitt Cancer Center, an incredibly famous cancer treatment and research center, and Fulgent Pharma, a nanobiotechnology firm, reported an essential organization pointed toward propelling cancer treatment through clinical turn of events and...
Fulcrum Therapeutics, Inc., a biotechnology firm declared that it has signed a collaboration and license agreement with Sanofi to develop and commercialize losmapimod, an oral small molecule being studied for the treatment of facioscapulohumeral...
Digital leaders and major players of the whole value chain gather at Pharmaceutical Automation and Digitalisation Congress (AUTOMA+ 2024) to share professional opinion on trends and latest solutions for the pharma digital transformation.
Zai Lab Limited, a biotechnology firm, declared that the National Medical Products Administration (NMPA) in China has endorsed the New Drug Application (NDA) for Augtyro (repotrectinib) for the therapy of grown-up patients with privately...
Sanofi, a leading pharmaceutical and healthcare firm, reports a venture of more than €1 billion to establish a new bioproduction limit at its locales in Vitry-sur-Seine (Val de Marne), Le Quality (Seine-Oceanic) and Lyon Gerland (Rhône)...
The US Food and Drug Administration has granted full clearance to Seagen Inc.'s Tivdak (tisotumab vedotin), which targets tissue factor (TF), for the treatment of patients with recurrent or metastatic cervical cancer who have progressed during or...
, CDSCO.jpg)
.jpg)